Key Takeaways
- Federal regulators sent ImmunityBio a formal warning letter regarding a television advertisement and podcast containing deceptive claims about ANKTIVA bladder cancer therapy
- The advertising content inaccurately implied ANKTIVA works against all cancer types — regulatory approval covers only one specific bladder cancer indication used with BCG therapy
- Regulators specifically named CEO Richard Adcock and Executive Chairman Dr. Patrick Soon-Shiong in connection with the violations
- ImmunityBio has received three separate FDA communications regarding promotional compliance issues since September 2025
- ImmunityBio must submit a corrective action plan within 15 working days to avoid potential legal consequences
Shares of ImmunityBio experienced a significant decline Tuesday following federal regulatory action targeting a television commercial and podcast episode that contained unauthorized claims about the approved applications of ANKTIVA, representing the company’s third regulatory intervention regarding marketing practices.
The FDA’s Office of Prescription Drug Promotion delivered a formal warning letter to ImmunityBio after reviewing a TV commercial and a podcast episode called “Is the FDA BLOCKING Life Saving Cancer Treatments?” Federal regulators concluded both pieces of content violated federal law.
The central problem involved overstatement of approved uses. ANKTIVA holds authorization for treating adult patients diagnosed with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors, delivered directly into the bladder in combination with BCG therapy.
The marketing content significantly exceeded that narrow approval. The materials implied ANKTIVA could “treat all cancers,” provide cancer prevention for individuals with radiation exposure, and function as a single-dose injection therapy. Federal regulators found no clinical evidence or approval supporting any of these assertions.
CEO Richard Adcock and Executive Chairman Dr. Patrick Soon-Shiong both participated in the promotional content and received specific mention in the FDA’s official correspondence.
Regulators determined the materials misbranded ANKTIVA and rendered the drug’s distribution in violation of the Federal Food, Drug, and Cosmetic Act.
Previous Regulatory Actions
ImmunityBio has faced similar regulatory scrutiny before. The FDA had sent untitled letters during September 2025 and January 2026 to Altor BioScience, an ImmunityBio subsidiary, addressing comparable promotional compliance concerns.
Tuesday’s correspondence represents the third such regulatory communication — and carries heightened seriousness. Warning letters from the FDA hold greater regulatory significance than untitled letters and demonstrate the agency’s growing concern.
Federal regulators also flagged ImmunityBio for inadequate presentation of risk information in the promotional materials and for excluding critical details about the drug’s authorized indication.
The podcast episode also failed to receive FDA submission at the time of its original release, constituting an additional regulatory requirement the company did not fulfill.
Investor Response
IBRX shares declined between 15% and 21% Tuesday, with certain reports indicating the drop reached 21% during early trading sessions.
ImmunityBio must provide the FDA with a written response within 15 working days detailing a plan to address the violations.
The company must also execute corrective communications directed at audiences who were exposed to the misleading promotional materials.
Federal regulators cautioned that inadequate corrective measures could trigger legal action.
